Market Closed -
Australian S.E.
01:39:51 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
0.043
AUD
|
0.00%
|
|
0.00%
|
-17.31%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
26.06
|
20.79
|
24.12
|
18.21
|
11.27
|
7.328
|
Enterprise Value (EV)
1 |
23.41
|
16.84
|
20.87
|
15.84
|
9.103
|
5.591
|
P/E ratio
|
-17.6
x
|
-16.6
x
|
-85.1
x
|
-46.5
x
|
-19.6
x
|
-0.72
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
125
x
|
65.4
x
|
81.9
x
|
949
x
|
119
x
|
553
x
|
EV / Revenue
|
113
x
|
53
x
|
70.8
x
|
826
x
|
95.8
x
|
422
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-31.6
x
|
-74.8
x
|
-159
x
|
-19.9
x
|
18.6
x
|
-29.3
x
|
FCF Yield
|
-3.16%
|
-1.34%
|
-0.63%
|
-5.02%
|
5.38%
|
-3.41%
|
Price to Book
|
8.77
x
|
1.83
x
|
2.15
x
|
1.68
x
|
0.88
x
|
2.64
x
|
Nbr of stocks (in thousands)
|
130,297
|
244,543
|
246,132
|
246,132
|
281,846
|
281,846
|
Reference price
2 |
0.2000
|
0.0850
|
0.0980
|
0.0740
|
0.0400
|
0.0260
|
Announcement Date
|
8/21/18
|
8/16/19
|
8/18/20
|
8/17/21
|
8/16/22
|
8/22/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.2078
|
0.3178
|
0.2946
|
0.0192
|
0.095
|
0.0133
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-0.7152
|
-0.6274
|
-0.2249
|
-0.3303
|
-0.4918
|
-0.488
|
Operating Margin
|
-344.1%
|
-197.43%
|
-76.34%
|
-1,721.13%
|
-517.61%
|
-3,679.9%
|
Earnings before Tax (EBT)
1 |
-1.468
|
-0.6927
|
-0.283
|
-0.3917
|
-0.5761
|
-10.17
|
Net income
1 |
-1.468
|
-0.6927
|
-0.283
|
-0.3917
|
-0.5761
|
-10.17
|
Net margin
|
-706.24%
|
-218.01%
|
-96.07%
|
-2,041.09%
|
-606.37%
|
-76,680.71%
|
EPS
2 |
-0.0114
|
-0.005133
|
-0.001151
|
-0.001591
|
-0.002043
|
-0.0361
|
Free Cash Flow
1 |
-0.7402
|
-0.2252
|
-0.1315
|
-0.7951
|
0.49
|
-0.1906
|
FCF margin
|
-356.13%
|
-70.86%
|
-44.62%
|
-4,143.37%
|
515.81%
|
-1,437.36%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/21/18
|
8/16/19
|
8/18/20
|
8/17/21
|
8/16/22
|
8/22/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2.65
|
3.94
|
3.25
|
2.37
|
2.17
|
1.74
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-0.74
|
-0.23
|
-0.13
|
-0.8
|
0.49
|
-0.19
|
ROE (net income / shareholders' equity)
|
-42.2%
|
-9.68%
|
-2.51%
|
-3.55%
|
-4.86%
|
-130%
|
ROA (Net income/ Total Assets)
|
-11.2%
|
-5.22%
|
-1.21%
|
-1.69%
|
-2.36%
|
-3.82%
|
Assets
1 |
13.11
|
13.28
|
23.33
|
23.19
|
24.37
|
266
|
Book Value Per Share
2 |
0.0200
|
0.0500
|
0.0500
|
0.0400
|
0.0500
|
0.0100
|
Cash Flow per Share
2 |
0.0200
|
0.0200
|
0.0100
|
0.0100
|
0.0100
|
0.0100
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/21/18
|
8/16/19
|
8/18/20
|
8/17/21
|
8/16/22
|
8/22/23
|
|
1st Jan change
|
Capi.
|
---|
| -17.31% | 9.09M | | +1.63% | 42.75B | | +47.70% | 41.61B | | +12.11% | 41.34B | | -8.83% | 26.59B | | +7.21% | 25.49B | | -23.07% | 18.12B | | +29.99% | 12.24B | | -2.27% | 11.76B | | +8.26% | 11B |
Other Biotechnology & Medical Research
|